Marinomed Biotech AG (VSE: MARI)

https://www.marinomed.com

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). *

	Start	2006-01-01 reorganised before
	Predecessor	Marinomed Biotechnologie GmbH
	Industry	Carragelose®
	Industry 2	Marinosolv® technology platform
	Person	Grassauer, Andreas (Marinomed Biotechnologie GmbH 201307 CEO)
	Person 2	Schmidt, Pascal (Marinomed 201808– CFO before Raymond James Financial + Mummert & Co + Infineon Ventures)

	Region	Wien (Vienna)
	Country	Austria
	Street	1 Veterinärplatz
	City	1210 Wien
	Tel	+43-1-2507744-60
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2023-12-31)
	Currency	EUR
	Annual sales	9,183,500 (revenues, annual (2023) 2023-12-31)
	Profit	-6,794,800 (2023-12-31)
	Cash	2,588,800 (2023-12-31)

		* Document for »About Section«: Marinomed Biotech AG. (8/14/24). "Press Release: Marinomed Biotech AG Aims for Financial Reorganization by Restructuring Proceedings without Self-administration". Korneuburg.

		Record changed: 2024-08-15